HNRNPA2B1 and viral infectious disease: Our data revealed that PAC5, a highly selective and potent agonist of hnRNPA2B1, initiates the TBK1-IRF3 pathway leading to upregulation of type I IFNs, phosphorylation of STAT1/2, and inhibition of viral infection in vivo and in vitro.